Correlation of Hemostatic Parameters with Poly (ADP-ribose) Polymerase-1 (PARP-1) Polymorphisms, Mutations, Laboratory, and Clinical Characteristics in 114 Patients with Philadelphia-Negative Myeloproliferative Neoplasms

Abstract

Patients with Philadelphia-negative myeloproliferative neoplasms (PN-MPN) are at a higher risk for venous thrombosis. Thromboelastometry may prove efficient to evaluate the patient's thrombotic risk. In this study, based on data from 114 patients with PN-MPN from a single center in Greece, hemostatic profile was assessed with routine coagulation tests, Rotational Thromboelastometry (ROTEM ® ), and Platelet Function Analyzer (PFA)-100 and correlated with clinical, laboratory, treatment characteristics, gene mutations and polymorphisms of poly (ADP-ribose) polymerase-1 (PARP-1). According to thromboelastometry parameters, patients with essential thrombocythemia (ET) had a more hypercoagulable status compared to patients with polycythemia vera (PV) and myelofibrosis (MF) while in all patients there was a statistically positive correlation between alpha angle and platelet (PLT) count and between maximum clot firmness (MCF) and PLT count (p < 0.001). In Janus kinase 2 (JAK2) positive patients with PV, the absence of the PARP-1 polymorphism was correlated with thrombosis during follow-up (p = 0.019). Among 47 patients under treatment with aspirin and complete platelet inhibition, no patient had a thrombotic episode in follow-up period (p = 0.006). Based on our results, global hemostatic assays in combination with other parameters could help identify patients with PN-MPN at higher thrombotic risk and adjust the type and dose of appropriate treatment.